Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
The widespread and long-term use of potent therapies designed to repress androgen receptor (AR) signaling is changing the molecular and phenotypic landscapes of prostate cancer. We conducted molecular profiling of metastatic castration-resistant prostate cancer (mCRPC) patient specimens and patient-derived xenograft models and identified five distinct mCRPC phenotypes. Herein, we characterize an AR-low phenotype that has low AR expression with concomitant decreases in a subset of AR regulated ge...
Provenance — who produced it, who reused it
Linked to 8 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Single-cell ATAC and RNA sequencing reveal pre-existing and pers... 2021 · 121 cites
- Dynamic prostate cancer transcriptome analysis delineates the tr... 2021 · 109 cites
6 further papers cite this accession but reuse could not be confirmed.
Deep data QC
100/100 · AStandardized, field-standard QC computed by touching the data — every metric states how it was obtained · evidence: measured
Large-scale human RNA-seq on HiSeq 2500 generating 6.44 billion reads across 643 Gb with 94.2% Q20 and 91.4% Q30 provides massive depth for sensitive transcript discovery. The low N-content (0.071%) and manageable dataset size enable comprehensive differential expression studies; particularly useful for detecting condition-specific isoforms or rare-variant expression effects.
The A grade is a transparent weighted average. Each metric below scored from 0–100% against the published bulk-RNA-seq thresholds, weighted by its importance; nothing is hidden or subjective.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0